Noninvasive Monitoring Strategies for Bronchopulmonary Dysplasia or Post-Prematurity Respiratory Disease: Current Challenges and Future Prospects

Definitions of bronchopulmonary dysplasia (BPD) or post-prematurity respiratory disease (PPRD) aim to stratify the risk of mortality and morbidity, with an emphasis on long-term respiratory outcomes. There is no univocal classification of BPD due to its complex multifactorial nature and the substantial heterogeneity of clinical presentation. Currently, there is no definitive treatment available for extremely premature very-low-birth-weight infants with BPD, and challenges in finding targeted preventive therapies persist. However, innovative stem cell-based postnatal therapies targeting BPD-free survival are emerging, which are likely to be offered in the first few days of life to high-risk premature infants. Hence, we need easy-to-use noninvasive tools for a standardized, precise, and reliable BPD assessment at a very early stage, to support clinical decision-making and to predict the response to treatment. In this non-systematic review, we present an overview of strategies for monitoring preterm infants with early and evolving BPD-PPRD, and we make some remarks on future prospects, with a focus on near-infrared spectroscopy (NIRS).

Automated summary

Definitions of bronchopulmonary dysplasia (BPD) or post-prematurity respiratory disease (PPRD) focus on categorizing mortality and morbidity risk, with an emphasis on long-term respiratory outcomes. Lack of a unified BPD classification and definitive treatment for extremely premature infants with BPD persists. However, stem cell-based postnatal therapies may offer hope for high-risk premature infants, while noninvasive tools like near-infrared spectroscopy (NIRS) can provide early, accurate, and reliable BPD assessment.